Reviewing Enliven Therapeutics (NASDAQ:ELVN) and NLS Pharmaceutics (NASDAQ:NLSP)

Enliven Therapeutics (NASDAQ:ELVN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Volatility & Risk

Enliven Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.

Valuation & Earnings

This table compares Enliven Therapeutics and NLS Pharmaceutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$89.02 million	($2.00)	-10.00
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A

Institutional and Insider Ownership

95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Enliven Therapeutics and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-29.15%	-27.88%
NLS Pharmaceutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enliven Therapeutics and NLS Pharmaceutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1	0	5	0	2.67
NLS Pharmaceutics	1	0	0	0	1.00

Enliven Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 106.00%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Enliven Therapeutics is more favorable than NLS Pharmaceutics.

Summary

Enliven Therapeutics beats NLS Pharmaceutics on 6 of the 9 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.